Table 3 Global gamma passing rates of volumetric modulated arc therapy (VMAT) plans with various gamma criteria
From: Prediction of VMAT delivery accuracy with textural features calculated from fluence maps
Treatment site | 2%/2 mm | 2%/1 mm | 1%/2 mm | 1%/1 mm | ||||
|---|---|---|---|---|---|---|---|---|
MC | AC | MC | AC | MC | AC | MC | AC | |
Trilogy | ||||||||
H&N | 96.3 ± 2.4 | 98.5 ± 2.1 | 90.1 ± 3.9 | 94.4 ± 3.7 | 87.8 ± 5.3 | 94.8 ± 3.9 | 72.7 ± 6.9 | 85.1 ± 6.4 |
Prostate (PP) | 95.3 ± 4.0 | 96.6 ± 2.8 | 87.6 ± 7.6 | 86.6 ± 7.4 | 89.3 ± 4.6 | 91.9 ± 4.2 | 72.2 ± 7.9 | 75.4 ± 8.2 |
Prostate (BP) | 96.8 ± 1.7 | 96.0 ± 4.1 | 91.9 ± 3.2 | 85.6 ± 7.9 | 92.0 ± 3.2 | 91.3 ± 5.9 | 79.1 ± 5.6 | 74.5 ± 9.8 |
Liver | 97.3 ± 2.6 | 98.2 ± 1.4 | 93.9 ± 3.9 | 92.3 ± 4.2 | 90.4 ± 4.1 | 94.5 ± 2.9 | 80.1 ± 6.4 | 82.9 ± 5.8 |
Spine | 96.4 ± 3.4 | 97.3 ± 1.6 | 91.5 ± 6.6 | 89.3 ± 6.8 | 91.0 ± 5.5 | 92.5 ± 2.5 | 79.0 ± 8.6 | 78.4 ± 7.7 |
TrueBeam STx | ||||||||
Lung (SABR) | 98.6 ± 1.5 | 99.0 ± 0.6 | 93.6 ± 2.9 | 93.2 ± 3.4 | 93.6 ± 3.8 | 97.5 ± 0.8 | 81.2 ± 6.4 | 89.2 ± 3.7 |
Spine (SABR) | 98.8 ± 1.2 | 98.9 ± 0.9 | 95.7 ± 2.4 | 95.3 ± 2.5 | 95.4 ± 2.5 | 97.1 ± 1.6 | 88.6 ± 4.2 | 89.2 ± 3.9 |
Liver (SABR) | 98.9 ± 1.3 | 98.6 ± 1.4 | 96.0 ± 2.9 | 93.7 ± 4.8 | 96.0 ± 2.3 | 96.5 ± 2.8 | 87.6 ± 6.5 | 87.3 ± 6.8 |
Brain | 97.6 ± 2.1 | 99.5 ± 0.6 | 95.0 ± 2.4 | 95.4 ± 5.0 | 92.5 ± 3.5 | 98.0 ± 1.6 | 84.5 ± 3.8 | 89.4 ± 7.2 |
H&N | 97.5 ± 1.6 | 99.6 ± 0.8 | 92.2 ± 3.8 | 98.3 ± 2.0 | 89.9 ± 3.1 | 97.4 ± 3.0 | 75.6 ± 5.7 | 93.1 ± 5.6 |